Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for metabolic research applications. This synthetic peptide demonstrates superior efficacy in glucose regulation studies compared to single-receptor agonists.
Our pharmaceutical grade Tirzepatide is supplied as a white lyophilized powder with 99.9% purity. The compound has shown promising results in clinical research for weight management applications, with studies demonstrating significant reductions in body mass index.
The molecular structure of Tirzepatide (C225H348N48O68) features a PEG-modified lysine side chain that enhances water solubility while maintaining biological activity. This modification contributes to the compound's extended half-life and sustained receptor binding properties.
Research indicates Tirzepatide's dual mechanism of action produces superior glycemic control compared to selective GLP-1 receptor agonists. The compound has received significant attention for its potential applications in metabolic syndrome research.
For research purposes only. Not for human consumption. Proper storage conditions are essential to maintain peptide stability - store in a cool, dry environment protected from light and moisture.